Valuation dashboard for Ligand Pharmaceuticals Incorporated (LGND) with P/E 144.08, P/B 6.70, EV/EBITDA 93.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Analysis Summary
Ligand Pharmaceuticals Incorporated reported revenue of $268.1M in the most recent fiscal year, growing at a 5-year CAGR of 10.4%.
Trailing-twelve-month margins: gross margin 107.1%, operating margin 11.9%, net margin 20.3%.
At $322.75 (closing price, October 30, 2026), LGND trades at a P/E of 144.08 and an ROE of 5.22%. Market capitalisation stands at $6.4B.
Balance sheet quality for LGND: debt-to-equity ratio of 1.17, current ratio of 13.35 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 144.08 |
| Price / Book | 6.70 |
| EV / EBITDA | 93.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorporated | $6.4B | 144.08 | 6.70 | 5.2% |
| AMGN | Amgen Inc. | $251.9B | 28.96 | 21.53 | 89.3% |
| INCY | Incyte Corporation | $24.4B | 64.04 | 4.34 | 7.1% |
| GMAB | Genmab A/S | $35.1B | 44.96 | 6.01 | 13.6% |
| EXEL | Exelixis, Inc. | $17.4B | 20.78 | 9.34 | 45.5% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.2B | 101.6% | ||
| ABBV | AbbVie Inc. | $521.1B | 83.08 | -223.7% | |
| PFE | Pfizer Inc. | $174.0B | 40.33 | 2.04 | 4.9% |
Price
| Price | $322.75 (closing price, October 30, 2026) |
| Market Cap | $6.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 5.22% |
| Return on Invested Capital | 2.29% |
| Return on Assets | 2.30% |
| Gross Margin | 107.11% |
| Operating Margin | 11.91% |
| Net Margin | 20.27% |
Related companies: AMGN · INCY · GMAB · EXEL · BCRX · ABBV · PFE · BMY
Explore sector: Healthcare · Biotechnology
More sections of LGND: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks